Split Realities for Sisters With Breast Cancer Gene
Agonizing questions raised by a family history of breast cancer hit sisters.
Oct. 8, 2007 — -- As sisters, Donata Earley and Karen Switzer share an incredible friendship — and a troubling legacy.
The family photographs that fill Switzer's dining room help tell the story.
"She had breast cancer, she had breast cancer and she had breast cancer," Switzer says, pointing to pictures of her great-grandmother, grandmother and mother. Their faces smile back in black and white.
For Switzer, 41, her family history was a constant worry.
"You always think … in the back of your mind, 'Could it be my turn next?'" she says.
So, both sisters asked their doctors for a blood test to determine whether they carry the genetic defect that raises their risk for getting breast cancer. Women without that defect have a 12 percent lifetime risk of getting the disease. For women with the mutation, the odds can range anywhere from 50 percent to 80 percent.
For Switzer and Earley, the news was expected, but painful, as both had mutations on the BRCA2 gene, one of a number of genes linked to breast cancer.
They were then faced with the painful choice to consider having a mastectomy to avoid breast cancer.
Switzer, with just her family history and an elevated risk of getting cancer — the married mother of a 6-year-old daughter and 4-year-old son — chose to have a double mastectomy and breast reconstruction.
"My objective, really, was I wanted to get this before it ever got me," says Switzer. "I wanted to be part of my husband's and children's lives for a long time to come. "
Earley, a 45-year-old single mother to a 20-year-old son, thought that someday she would do the same.
She had just started a new job and planned to wait a year before surgery.
But six months later, she found a lump. It was breast cancer.
"I'm embarrassed to say I waited as long as I did," she says. "I'm embarrassed to admit I did have a choice. I was in the know and still decided to hold off."
The availability of the blood test, marketed by Myriad Genetics, and a recent advertising campaign to promote it, have raised concerns about whether the ads create undue anxiety about a diagnosis that may never come.
